Hepatocellular Carcinoma | China In-Depth | China – 2023
Hepatocellular carcinoma is one of the most common liver cancers and has a five-year survival rate of only 18%. China represents more than half of all diagnosed cases of liver cancer worldwide. The market in China is poised to experience substantial growth over the 2022-2032 forecast period. Key market drivers include the continued uptake of immune checkpoint inhibitors and combination therapies—Tecentriq plus bevacizumab and Tyvyt plus Byvasda—as well as the anticipated launch and uptake of several targeted therapies in the next 10 years. In this report, we examine how clinical and nonclinical factors (e.g., price dynamics, inclusion in China’s National Reimbursement Drug List) will influence the treatment paradigm in this market during the forecast period. We anticipate that the recent reforms in China’s regulatory and reimbursement landscape will encourage both domestic and multinational manufacturers to enter the growing hepatocellular carcinoma therapy market in China.
Questions answered
- What is the diagnosed incidence of hepatocellular carcinoma in China, and how are patients treated today? Are there any differences in the management strategies in urban versus rural China?
- Which are the most commercially relevant drugs in this market and why?
- What are interviewed experts’ insights into current treatment options? What are the key unmet needs in the management of hepatocellular carcinoma?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers of and constraints in this market, and how will the market evolve during the forecast period?
Content highlights
Geography: China.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with medical oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of hepatocellular carcinoma in urban versus rural China. Clinically and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key hepatocellular carcinoma regimens through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: > 15 drugs; Phase II: > 16 drugs; Phase I/II: 10; coverage of select Phase I products.
Product description
China-In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
